Critical Reviews in Oncology / Hematology
Volume 74 , Pages S7-S10 , April 2010

Bone targeted therapy in breast cancer: present and future

  • Jens Huober

      Affiliations

    • Corresponding Author InformationCorresponding author. Prof. Dr. med. Jens Huober, Breast Center, Kantonsspital St. Gallen, CH-9007 St. Gallen, Switzerland. Tel.: +41 71 494 1177; fax: +41 71 494 6368; URL: www.brustzentrum-kssg.ch
    • ,
  • Beat Thürlimann

References 

  1. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
  2. Theriault RL , Lipton A , Hortobagyi GN , et al.   Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial . J Clin Oncol . 1999;17:846–854
  3. Berenson JR , Rosen LS , Howell A , et al.   Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases . Cancer . 2001;91:1191–1200
  4. Hillner BE , Ingle JN , Chlebowski RT , et al.   American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer . J Clin Oncol . 2003;21:4042–4057
  5. Aapro M , Abrahamsson PA , Body JJ , et al.   Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel . Ann Oncol . 2008;19:420–432
  6. Bundred NJ , Campbell ID , Davidson N , et al.   Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results . Cancer . 2008;112:1001–1010
  7. Gnant M , Mlineritsch B , Luschin-Ebengreuth G , et al.   Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy . Lancet Oncol . 2008;9:840–849
  8. Braun S , Vogel F , Naume B , et al.   A pooled analysis of bone marrow micrometastasis in breast cancer . N Engl J Med . 2005;353:793–802
  9. Powles T , Paterson S , Kanis JA , et al.   Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer . J Clin Oncol . 2002;20:3219–3224
  10. Powles T , Paterson A , McCloskey E , et al.   Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer . Breast Cancer Res . 2006;8:1–7
  11. Saarto T , Blomqvist C , Virkkunen P , et al.   Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial . J Clin Oncol . 2001;19:10–17
  12. Saarto T , Vehmanen L , Virkkunen P , et al.   Ten-year follow up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients . Acta Oncol . 2003;43:650–656
  13. Diel IJ , Solomayer E , Costa SD , et al.   Reduction in new metastases in breast cancer with adjuvant clodronate treatment . N Engl J Med . 1998;339:357–363
  14. Diel IJ , Jaschke A , Solomayer E , et al.   Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long term follow up . Ann Oncol . 2008;19:2007–2011
  15. Kristensen B , Ejlertsen B , Mouridsen H , et al.   Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer . Acta Oncol . 2008;47:740–746
  16. Gnant M , Eidtmann H . The anti-tumor effect of bisphosphonates -ABCSG-12, ZO-FAST and more … . Crit Rev Oncol Hematol . 2010;74(1):S2–S6
  17. Diel I , Aebi S . Routine adjuvant use of bisphosphonates in breast cancer - Arguments in favour and against . Crit Rev Oncol Hematol . 2010;74(1):S11–S15
  18. Lipton A , Steger GG , Figueroa J , et al.   Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases . J Clin Oncol . 2007;25:4431–4437
  19. Fizazi K , Lipton A , Mariette X , et al.   Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer or other neoplasms after intravenous bisphosphonates . J Clin Oncol . 2009;27:1546–1571
  20. Stopeck A , Body JJ , Fujiwara Y , et al.   Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study . EJC Suppl . 2009;7(3):2; [abstract 2LBA].
  21. Stopeck A , de Boer R , Fujiwara Y , et al.   Comparison of denosumab versus zoledronic acid on the incidence of skeletal-related events in breast cancer patients with bone metastases . Cancer Res . 2009;69(suppl): abstract 22.
  22. Ellis GK , Bone HG , Chlebowski R , et al.   Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer . J Clin Oncol . 2008;26:4875–4882
  23. Background documentation for meeting of Advisory Committee for reproductive health drugs (August 13, 2009). Denosumab . http://www.fda.gov

PII: S1040-8428(10)70004-4

doi: 10.1016/S1040-8428(10)70004-4

Critical Reviews in Oncology / Hematology
Volume 74 , Pages S7-S10 , April 2010

Article Tools